Biomarkers for the risk of thrombosis in pancreatic adenocarcinoma are related to cancer process

Background Venous thrombo-embolic events (VTE) frequently occur in patients with pancreatic ductal adenocarcinoma (PDAC) and contribute to high morbidity and mortality. Objectives To determine whether VTE biomarkers are related to cancer, inflammation or precancerous states and to assess their relevance to predict VTE in PDAC. Patients and Methods We compared VTE biomarkers in patients with PDAC (n = 42), intraductal papillary mucinous neoplasm of the pancreas (IPMN, n = 48) or chronic pancreatitis (n = 50). PDAC patients were followed-up for 6 months. Results Factor VIII, D-dimers, von Willebrand factor, free tissue factor pathway inhibitor and microvesicle-tissue factor (MV-TF) activity were higher in PDAC patients compared to patients with IPMN or chronic pancreatitis. PDAC patients with metastasis presented higher D-dimers and MV-TF activity compared to patients with localized lesions, but elevation of D-dimers was dependent on tumor size. In multivariate analysis, elevated D-dimers (≥2.16 µg/mL) or MV-TF activity (≥2.37 pg/mL) were significant risk factors for VTE in PDAC patients, after adjustment for age and sex (HR 4.9 [1.0–23.1] or HR 10.5 [1.5–72.4], mean [interquartile range], respectively). Cumulative probability of VTE at 6 months was higher in patients with elevated D-dimers (56.3% vs 15.6%, p = 0.009) and in patients with high MV-TF activity (74.3% vs 21.7%, p = 0.01). Conclusions VTE biomarkers including D-dimers and MV-TF activity are not related to inflammation but rather to cancer process and dissemination. D-dimers and MV-TF activity are associated to future VTE in PDAC patients and could help identify patients who could benefit from thromboprophylaxis.

[1]  B. Engelmann,et al.  Distinct Pathogenesis of Pancreatic Cancer Microvesicle–Associated Venous Thrombosis Identifies New Antithrombotic Targets In Vivo , 2018, Arteriosclerosis, thrombosis, and vascular biology.

[2]  N. Mackman,et al.  Human pancreatic tumors grown in mice release tissue factor‐positive microvesicles that increase venous clot size , 2017, Journal of thrombosis and haemostasis : JTH.

[3]  V. Heinemann,et al.  Incidence, outcome and risk stratification tools for venous thromboembolism in advanced pancreatic cancer - A retrospective cohort study. , 2017, Thrombosis research.

[4]  R. Bertina,et al.  Tissue factor-bearing microparticles and CA19.9: two players in pancreatic cancer-associated thrombosis? , 2016, British Journal of Cancer.

[5]  N. Mackman,et al.  Tissue factor–positive tumor microvesicles activate platelets and enhance thrombosis in mice , 2016, Journal of thrombosis and haemostasis : JTH.

[6]  W. Chung,et al.  Comorbid risks of deep vein thrombosis and pulmonary thromboembolism in patients with chronic pancreatitis: a nationwide cohort study , 2016, Journal of thrombosis and haemostasis : JTH.

[7]  Wei Sun,et al.  Clinical and Prognostic Significance of Coagulation Assays in Pancreatic Cancer Patients With Absence of Venous Thromboembolism , 2015, American journal of clinical oncology.

[8]  X. Qi,et al.  Prevalence of Splanchnic Vein Thrombosis in Pancreatitis: A Systematic Review and Meta-Analysis of Observational Studies , 2015, Gastroenterology research and practice.

[9]  H. Sørensen,et al.  Splanchnic venous thrombosis is a marker of cancer and a prognostic factor for cancer survival. , 2015, Blood.

[10]  N. Mackman,et al.  Venous thrombosis and cancer: from mouse models to clinical trials , 2015, Journal of thrombosis and haemostasis : JTH.

[11]  D. Wagner,et al.  Tissue factor expressed by circulating cancer cell‐derived microparticles drastically increases the incidence of deep vein thrombosis in mice , 2015, Journal of thrombosis and haemostasis : JTH.

[12]  R. Fisker,et al.  Venous thrombosis in pancreaticobiliary tract cancer: outcome and prognostic factors , 2015, Journal of thrombosis and haemostasis : JTH.

[13]  P. Grzelak,et al.  Preoperative high level of D-dimers predicts unresectability of pancreatic head cancer. , 2014, World journal of gastroenterology.

[14]  I. Pabinger,et al.  Biomarkers for prediction of venous thromboembolism in cancer. , 2013, Blood.

[15]  A. Khorana,et al.  Circulating microparticle tissue factor, thromboembolism and survival in pancreaticobiliary cancers. , 2013, Thrombosis research.

[16]  R Lacroix,et al.  Standardization of pre‐analytical variables in plasma microparticle determination: results of the International Society on Thrombosis and Haemostasis SSC Collaborative workshop , 2013, Journal of thrombosis and haemostasis : JTH.

[17]  A. Kaider,et al.  Microparticle‐associated tissue factor activity in patients with pancreatic cancer: correlation with clinicopathological features , 2013, European journal of clinical investigation.

[18]  A. Khorana,et al.  Incidence and predictors of venous thromboembolism (VTE) among ambulatory high‐risk cancer patients undergoing chemotherapy in the United States , 2013, Cancer.

[19]  D. Vidaud,et al.  Extrahepatic Portal Venous System Thrombosis in Recurrent Acute and Chronic Alcoholic Pancreatitis Is Caused by Local Inflammation and Not Thrombophilia , 2012, The American Journal of Gastroenterology.

[20]  O. Wagner,et al.  High D-dimer levels are associated with poor prognosis in cancer patients , 2012, Haematologica.

[21]  C. Marosi,et al.  Microparticle‐associated tissue factor activity, venous thromboembolism and mortality in pancreatic, gastric, colorectal and brain cancer patients , 2012, Journal of thrombosis and haemostasis : JTH.

[22]  Derick R. Peterson,et al.  Symptomatic and incidental thromboembolism are both associated with mortality in pancreatic cancer , 2011, Thrombosis and Haemostasis.

[23]  C. Marosi,et al.  Prediction of venous thromboembolism in cancer patients. , 2010, Blood.

[24]  D. Neuberg,et al.  Tumor-Derived Tissue FactorBearing Microparticles Are Associated With Venous Thromboembolic Events in Malignancy , 2009, Clinical Cancer Research.

[25]  D. Lombardo,et al.  Cancer cell–derived microparticles bearing P-selectin glycoprotein ligand 1 accelerate thrombus formation in vivo , 2009, The Journal of experimental medicine.

[26]  R. White,et al.  Venous Thromboembolism (VTE) in Patients with Cancer: Epidemiology and Risk Factors , 2009, Cancer investigation.

[27]  A. Khorana,et al.  Plasma tissue factor may be predictive of venous thromboembolism in pancreatic cancer , 2008, Journal of thrombosis and haemostasis : JTH.

[28]  J. Colon,et al.  Tissue factor‐bearing microparticles derived from tumor cells: impact on coagulation activation , 2008, Journal of thrombosis and haemostasis : JTH.

[29]  Gary H Lyman,et al.  Development and validation of a predictive model for chemotherapy-associated thrombosis. , 2008, Blood.

[30]  J. Ringel,et al.  Expression of tissue factor in pancreatic adenocarcinoma is associated with activation of coagulation. , 2006, World journal of gastroenterology.

[31]  R. Bertina,et al.  Microparticle‐associated tissue factor activity: a link between cancer and thrombosis? , 2007, Journal of thrombosis and haemostasis : JTH.

[32]  S. Hirohashi,et al.  Prognostic Significance of Tissue Factor in Pancreatic Ductal Adenocarcinoma , 2005, Clinical Cancer Research.

[33]  N. Lemoine,et al.  Tissue factor expression correlates with histological grade in human pancreatic cancer , 1995, The British journal of surgery.

[34]  A. M. Muñoz Martín,et al.  Incidence of venous thromboembolism (VTE) in ambulatory pancreatic cancer patients receiving chemotherapy and analysis of Khorana’s predictive model , 2014, Clinical and Translational Oncology.